Propofol is an intravenous general anesthetic that alters neuronal excitability by modulating agonist responses of pentameric ligandgated ion channels (pLGICs). Evidence suggests that propofol enhancement of anion-selective pLGICs is mediated by a binding site between adjacent subunits, whereas propofol inhibition of cation-selective pLGICs occurs via a binding site contained within helices M1-M4 of individual subunits. We considered this idea by testing propofol modulation of homomeric human glycine receptors (GlyRs) and nematode glutamate-gated chloride channels (GluCls) recombinantly expressed in Xenopus laevis oocytes with electrophysiology. The Haemonchus contortus AVR-14B GluCl was inhibited by propofol with an IC 50 value of 252 Ϯ 48 M, providing the first example of propofol inhibition of an anion-selective pLGIC. Remarkably, inhibition was converted to enhancement by a single I18ЈS substitution in the channel-forming M2 helix (EC 50 ϭ 979 Ϯ 88 M). When a previously identified site between adjacent subunits was disrupted by the M3 G329I substitution, both propofol inhibition and enhancement of GluCls were severely impaired (IC 50 and EC 50 values could not be calculated). Similarly, when the equivalent positions were examined in GlyRs, the M2 S18ЈI substitution significantly altered the maximum level of enhancement by propofol, and the M3 A288I substitution abolished propofol enhancement. These data are not consistent with separate binding sites for the opposing effects of propofol. Instead, these data suggest that propofol enhancement and inhibition are mediated by binding to a single site in anion-selective pLGICs, and the modulatory effect on channel gating depends on the M2 18Ј residue.
Introduction
The general anesthetic propofol (2,6-diisopropylphenol) decreases neuronal excitability in humans by enhancing agonistinduced activation of type A GABA and glycine receptors (GABA A Rs and GlyRs), anion-selective members of the pentameric ligand-gated ion channel (pLGIC) family (Zeller et al., 2008; Nguyen et al., 2009) . Photolabeling with propofol analogues (Yip et al., 2013) , propofol inhibition of introduced cysteine labeling (Bali and Akabas, 2004) , and conventional mutagenesis experiments (Krasowski et al., 1998) suggest that propofol binds between adjacent subunits in GABA A Rs at a site overlapping that of the nonconventional agonist ivermectin in nematode glutamategated chloride channels (GluCls; Hibbs and Gouaux, 2011) . In contrast, cation-selective 5-hydroxytryptamine-gated pLGICs (5-HT3Rs; Rüsch et al., 2007) and acetylcholine-gated pLGICs (nAChRs; Flood et al., 1997) are inhibited by propofol, and the only propofol/pLGIC crystal structure available shows propofol bound within membrane-spanning helices M1-M4 of individual subunits of GLIC, a bacterial cation-selective pLGIC that is inhibited by propofol (Nury et al., 2011) . This raises the possibility that enhancement and inhibition of pLGICs are mediated by distinct propofol binding sites: enhancement by an intersubunit site; and inhibition by an intrasubunit site. In support of this idea, x-ray crystallography and mutagenesis results at GLIC suggest that the intersubunit site by which enhancement occurs is naturally obscured by a phenylalanine side chain at the M2 14Ј position that is conserved in cation-selective pLGICs (Sauguet et al., 2013) ; GlyRs, by contrast, possess a smaller glutamine residue at this position, allowing propofol to bind between subunits and enhance channel gating (Sauguet et al., 2013) .
These structural hypotheses were recently put to functional tests in GLIC. Propofol binding to GLIC increased accessibility to the site contained within single subunits (Ghosh et al., 2013) , and mutations in this cavity did not impair propofol inhibition (Ghosh et al., 2013; Sauguet et al., 2013) . Both of these results are inconsistent with a mechanism of inhibition in which propofol binds to a site within individual subunits. Thus, the question remains as to why propofol enhances or inhibits various pLGICs. In an attempt to address this question, we examined propofol modulation of two anion-selective pLGICs, the human ␣1 GlyR and the Haemonchus contortus AVR-14B GluCl. We discovered that the AVR-14B GluCl, unlike GlyRs and GABA A Rs, is inhibited by propofol. Furthermore, a single M2 substitution that altered the efficacy of propofol enhancement of GlyRs converted propofol inhibition of AVR-14B GluCls to enhancement. This enabled us to test propofol-inhibited and propofol-enhanced AVR-14B GluCls for altered propofol sensitivity upon substitution of an M3 residue at the site between adjacent subunits. In GlyRs, propofol-inhibited GluCls, and propofol-enhanced GluCls, the M3 substitution dramatically impaired propofol modulation. These results point to a new explanation for the opposing effects of propofol modulation of pLGICs, in which propofol binds to a single site between subunits, and the effect on channel gating depends on a remote M2 position.
Materials and Methods
Reagents. Glycine, NaCl, KCl, CaCl 2 , MgCl 2 , HEPES, and dimethyl sulfoxide were purchased from Carl Roth; NaOH from AppliChem; and L-glutamate, propofol (2,6-diisopropylphenol), tricaine, gentamycin, and type IIA collagenase from Sigma-Aldrich. One mole stocks of glycine and L-glutamate were prepared in bath solution (see Oocyte preparation and electrophysiology). One mole stocks of propofol were prepared in dimethyl sulfoxide. Stocks were stored at Ϫ20°C, and dilutions were prepared directly before experiments. NotI and XbaI were purchased from New England Biolabs; the Quikchange II XL Site-Directed Mutagenesis kit from Agilent Technologies; and mMESSAGE mMACHINE transcription kits from Life Technologies.
Site-directed mutagenesis and cRNA synthesis. The human ␣1 GlyR subunit cDNA in the pNKS2 vector (Haeger et al., 2010) and the H. contortus AVR-14B (also called ␣3B and GBR-2B) GluCl subunit cDNA in the T7 vector (McCavera et al., 2009 ; kindly provided by Professor Adrian J. Wolstenholme, University of Georgia) were used for cRNA synthesis and site-directed mutagenesis. Mutant cDNAs were generated with the Quikchange II XL Site-Directed Mutagenesis kit. Sequences of entire GlyR or GluCl inserts were confirmed (Eurofins MWG Operon) and cDNAs were linearized with NotI (GlyR) or XbaI (GluCl) and transcribed with SP6 (GlyR) or T7 (GluCl) transcription kits.
Oocyte preparation and electrophysiology. Female Xenopus laevis frogs were anesthetized with 0.3% tricaine, and oocytes were surgically removed, in accordance with the Technical University of Darmstadt . Oocytes were transferred to ND96 solution with the following components (in mM): 96 NaCl, 2 KCl, 1 CaCl 2 , 1 MgCl 2 , 5 HEPES, pH 7.4 with NaOH, supplemented with 50 mg/ml gentamycin. Stage V or VI oocytes were isolated and then defolliculated by 2 h incubation in type IIA collagenase. Oocytes were then rinsed with Ca 2ϩ -free ND96 for 10 min and stored in ND96 at 4°C until cRNA injection. Four nanograms of 100 ng/l cRNAs were injected into oocytes, which were then stored in ND96 at 18°C until experiments 2-4 d later. In experiments, oocytes were continuously perfused in a plastic recording chamber with bath solution comprising the following components (in mM): 115 NaCl, 1 KCl, 1.8 CaCl 2 ,10 HEPES, pH 7.4 with NaOH. Oocytes were clamped at Ϫ70 mV by two-electrode voltage-clamp with microelectrodes containing 3 M KCl. Currents were acquired at 200 Hz with a Geneclamp 500B amplifier, a Digidata 1322A digitizer, and Clampex 9.2 software (Molecular Devices). Glutamate or glycine, dissolved in bath solution, was applied alone or after 30 s preapplication of propofol, also dissolved in bath solution.
Data analysis. Currents were measured with Clampfit 9.2 software (Molecular Devices), and all subsequent data analyses, including statistical tests, were performed in Prism 4 (GraphPad Software). Peak current responses to glycine or glutamate were plotted against agonist concentration and fit with variable slope nonlinear regression to establish agonist EC 50 values and Hill slope (n H ) parameters; mean Ϯ SEM are reported. For propofol enhancement, responses to EC 20 glycine or EC 20 glutamate after propofol application were divided by the response without propofol, and from this value, 1 was subtracted, giving "fold enhancement" reported in figures and text. In this way, a value of 0 equates to no effect of propofol on agonist responses. For propofol inhibition, responses to EC 50 glutamate after propofol application were divided by the response without propofol, giving the remaining fractional current indicated in figures; in the main text, percentage inhibition of the control response is reported. Propofol-induced fold enhancement or remaining fractional current were fit with variable slope nonlinear regression (Prism 4), giving propofol EC 50 or IC 50 values and n H parameters for each individual experiment; means Ϯ SEM for the different constructs are reported. In all experiments, each construct was tested in at least two batches of oocytes, alongside at least two other constructs. Means for mutants were compared with means for WT and means for glutamateinduced activation were compared with means for glutamate-induced activation in the presence of a single concentration of propofol by unpaired Student's t test. Differences with a p value Ͻ0.05 were considered significant; absolute p values are reported in the main text.
Sequence alignment and homology modeling. All sequence alignments, including that in Figure 2 and those used for homology modeling were performed with ClustalW (Goujon et al., 2010) . The H. contortus AVR-14B GluCl (McCavera et al., 2009 ) model was based on the crystal structure of a truncated ␣ GluCl from Caenorhabditis elegans in complex with glutamate and ivermectin (PDB 3RIF; Hibbs and Gouaux, 2011) . In generating this model, AVR-14B amino acids aligning with truncated segments of 3RIF were removed from the AVR-14B sequence, leaving a truncated AVR-14B subunit of 338 aa with 61% sequence identity with 3RIF. The model was generated on the Swiss-Model homology modeling server (Arnold et al., 2006) and refined on the KoBaMIN server for knowledge-based energy minimization (Rodrigues et al., 2012) . Refinement increased the Qualitative Model Energy Analysis (QMEAN) score for predicted reliability from 0.496 to 0.512 (Benkert et al., 2008 ). The refined structure was then assessed and figures were generated in PyMol v1.4.1 (Schrödinger). Figure 1 shows an ␣1 GlyR model that is also built on PDB 3RIF and was previously described (Lynagh et al., 2011) .
Results
To address the possibility that size or polarity of the Q14Ј side chain determines propofol actions at anion-selective pLGICs, as raised by Sauguet et al. (2013) , we tested the effects of propofol on glycine-gated currents at mutant Q14ЈF, Q14ЈE, and Q14ЈK ␣1 GlyRs (Fig. 1A) . Propofol enhanced all mutant GlyRs (Fig. 1A,B) , without differing significantly from the wild-type (WT) propofol EC 50 value of 690 Ϯ 100 M, n H value of 2.4 Ϯ 0.4, and maximal 3.0 Ϯ 0.2-fold enhancement (n ϭ 5; all mutant values compared Figure 1 . Differential effects of M2 S18Ј and M3 A288 mutations on propofol potency at GlyRs. A, EC 20 glycine-gated currents at WT and mutant Q14ЈF, S18ЈI, and A288I ␣1 GlyRs in the presence of propofol. Scale bars: x, 30 s; y, 0.5 A. B, Propofol enhancement (mean Ϯ SEM) of WT and mutant GlyRs (as labeled on graph). C, Position of Q14Ј, S18Ј, and A288 side chains in ␣1 GlyR homology model. M1-M4 helices from two adjacent subunits (1 red, 1 blue) are viewed from above; their arrangement in the pentamer is shown at bottom right.
with WT value with Student's t test), indicating that the 14Ј side chain does not determine propofol enhancement of GlyRs. Given that M2 hydroxyl side chains pose a direct means for ligands to enhance channel gating of pLGICs (Hibbs and Gouaux, 2011), we considered other upper-M2 residues as possible determinants of propofol enhancement of GlyRs. We focused on the 18Ј position, as 18Ј mutations in GLIC alter propofol potency and channel gating (Nury et al., 2011; Ghosh et al., 2013) and the adjacent 17Ј position binds ortho-propofol diazirine in GABA A Rs (Yip et al., 2013) . To test the requirement of a small polar side chain at this position for propofol enhancement, we generated mutant S18ЈI GlyRs. These were enhanced with significantly greater potency than WT GlyRs, with an EC 50 value of 132 Ϯ 29 M (n ϭ 5; p ϭ 0.006) and maximal 4.7 Ϯ 0.7-fold enhancement ( p ϭ 0.029; Fig.  1A,B ; n H ϭ 2.6 Ϯ 0.3, not significantly different from WT). This indicates that although a small polar side chain at the 18Ј position is not required for propofol enhancement, this position may be allosterically involved in coupling propofol binding to channel gating. An allosteric involvement of S18Ј in propofol actions is supported by the distance separating S18Ј from a putative propofol binding cavity between subunits that includes the M3 A288 residue (Fig. 1C) . To verify these ideas, we tested mutant A288I and S18ЈI/ A288I GlyRs for propofol enhancement of glycine-gated currents. At both of these mutants, glycine-gated currents were insensitive to propofol at concentrations up to 10 mM (n ϭ 4; Fig. 1 A, B) , which is consistent with a direct role of A288 in propofol binding and an allosteric role of S18Ј in propofol enhancement of channel gating.
We next considered possible mechanisms of propofol modulation of invertebrate GluCls, given the structural template of the Caenorhabditis elegans ␣ GluCl crystal structure (Hibbs and Gouaux, 2011) and the accuracy with which GluCl modulation can describe human pLGIC modulation (Hibbs and Gouaux, 2011; Lynagh et al., 2011) . We therefore tested propofol modulation of the H. contortus AVR-14B GluCl, which is 66% identical to the C. elegans ␣ GluCl regarding M1-M4 helices and possesses the advantage of robust responses to the agonist glutamate (Cully et al., 1994; McCavera et al., 2009) . In a similar concentration range to its enhancement of GlyRs, propofol inhibited glutamate-gated currents at GluCls ( Fig.  2A) , with an IC 50 value of 252 Ϯ 48 M and n H value of 2.4 Ϯ 0.5 (n ϭ 6). The presence of 300 M propofol shifted the glutamate EC 50 value from 30 Ϯ 2 M to 60 Ϯ 12 M (n ϭ 4; p ϭ 0.037), decreased the maximal glutamate-induced current to 43 Ϯ 4% initial levels ( p ϭ 0.040; Fig. 2A) , and did not significantly affect the glutamate n H value (1.6 Ϯ 0.3 without propofol; 1.3 Ϯ 0.1 with propofol). These data provide the first example of propofol inhibition of an anion-selective pLGIC. GluCls possess a Q14Ј residue like GlyRs (Fig. 2 B, C) , in line with the idea that the 14Ј side chain does not determine propofol modulation of anion-selective pLGICs. The 18Ј isoleucine, however, contrasts the smaller serine or alanine residue at this position in GlyR and GABA A R ␣ subunits and more closely reflects the 18Ј valine in GLIC (Fig. 2 B, C) . To test whether the 18Ј side chain allosterically mediates propofol modulation of GluCls, as was the case in GlyRs, we tested the effects of propofol on glutamate-gated currents at mutant I18ЈS AVR-14B GluCls. Remarkably, inhibition was converted to enhancement (Fig. 2D) , with an EC 50 value of 979 Ϯ 88 M, n H value of 2.1 Ϯ 0.3, and maximal 3.6 Ϯ 0.4-fold enhancement (n ϭ 7). Seven hundred micromole propofol shifted the glutamate EC 50 value of 108 Ϯ 13 M to 41 Ϯ 5 M at I18ЈS GluCls (n ϭ 4; p ϭ 0.003; Fig. 2D ) without increasing maximal glutamate-gated currents or significantly affecting the n H value of 1.8 Ϯ 0.2, indicating that propofol enhances only submaximal current responses or increases apparent agonist affinity in I18ЈS GluCls. This reflects the leftward shift propofol induces in glycine and GABA dose-response relationships in human pLGICs (Orser et al., 1994; O'Shea et al., 2004) .
To test whether propofol enhancement of mutant I18ЈS GluCls occurs via a similar mechanism as in GlyRs and GABA A Rs, we tested the effects of the G329I substitution, as mutations at the equivalent position in GlyRs (A288; present study) and GABA A Rs (Krasowski et al., 2001 ) abolish propofol enhancement. We generated I18ЈS/G329I GluCls and found that at concentrations Յ3 mM, propofol had no effect on glutamate-gated currents (Fig. 3A) . This result is consistent with propofol enhancement occurring by propofol binding to a site between adjacent subunits. In a final test, we sought to compare propofol inhibition of WT GluCls and propofol enhancement of I18ЈS GluCls in terms of their structural requirements at the putative binding site between subunits. We reasoned that if binding sites for enhancement and inhibition were different, the G329I substitution alone would have no effect on propofol inhibition of GluCls. However, G329I GluCls showed dramatically decreased propofol sensitivity, with 3 mM propofol inhibiting only 12 Ϯ 7% of the EC 50 glutamate-induced current (Fig. 3B) , suggesting that, like propofol enhancement, propofol inhibition depends on a site between adjacent subunits.
Discussion
In the present study, we found that in two different anionselective pLGICs, substitution of the M2 18Ј residue altered the efficacy with which propofol modulates agonist responses, to the extent that inhibition was converted to enhancement in the AVR-14B GluCl. Also, substitution of an M3 alanine (in the ␣1 GlyR) or M3 glycine (in the AVR-14B GluCl) at the intersubunit site abolished enhancement and severely impaired inhibition of WT and/or mutant receptors. The simplest interpretation of the present results is that propofol binds to a single intersubunit site in anionic pLGICs, and the efficacy of modulation depends on the M2 18Ј residue. This interpretation relies heavily on the assumption that impaired propofol sensitivity upon M3 mutations is a result of an altered binding site and that the altered efficacy of propofol modulation upon M2 mutations is due to altered channel gating, but it is consistent with previous experiments at GABA A Rs and is supported by the actions of ivermectin at anionselective pLGICs. In GABA A Rs, propofol inhibits the labeling of an introduced cysteine at the equivalent M3 position (Bali and Akabas, 2004) and the binding of azietomidate to M3 and M1 residues at the intersubunit site (Li et al., 2010) . Ivermectin binds between helices of adjacent subunits in GluCls (Hibbs and Gouaux, 2011) and GlyRs (Lynagh et al., 2011) , and whereas ␣1 GlyR A288 and AVR-14B GluCl G329 mutations abolish ivermectin enhancement and/or activation (Lynagh and Lynch, 2010; Lynagh et al., 2011), ␣1 GlyR M2 side chain substitutions can alter the direction of modulation without affecting the concentrations required for modulation (Lynagh et al., 2011) .
New knowledge of propofol inhibition of GluCls and of the allosteric role of the 18Ј residue in propofol modulation sheds some light on the possible roles of other residues. Figure 2C shows that both ␣1 GlyRs, which are enhanced by propofol, and AVR-14B GluCls, which are inhibited, both possess serine and glycine residues at the M2 16Ј and 17Ј residues, respectively. These two positions are therefore unlikely to determine whether propofol binding enhances or inhibits agonist-gated currents. The 18Ј residue thus plays a specific role in linking propofol binding to agonist-gated currents, perhaps reflected in the increased agonist EC 50 values at GlyR and GluCl 18Ј mutants. A critical role for the upper end of M2 is also consistent with the labeling of M2 17Ј in GABA A Rs by ortho-propofol diazirine (Yip et al., 2013) and the negligible effects of M2 15Ј mutations on ␣1 GlyR modulation by propofol (Ahrens et al., 2008) . Although the intersubunit site is significantly larger than a single propofol molecule (Murail et al., 2011) , the present results suggest that lower residues of this site can be excluded as the principal determinants of propofol binding and modulation, which is consistent with the suggestions of Yip et al. (2013) regarding GABA A Rs.
Propofol enhancement or inhibition of different anionselective pLGICs via a single site in the membrane-spanning domain opens the door to bidirectional pharmacological targeting of different pLGIC subtypes via a conserved binding site. This may even apply to cation-selective nAChRs and 5-HT 3 Rs, given the recent findings that propofol inhibition of GLIC is unlikely to occur via the intrasubunit binding site (Ghosh et al., 2013) and that nAChRs possess both intrasubunit and intersubunit binding sites for propofol analogues (Jayakar et al., 2013) .
